1	Using clustering of genetic variants in Mendelian
2	randomization to interrogate the causal pathways
3	underlying multimorbidity
4	Xiaoran Liang ^{*a} Ninon Mounier ^{a} , Nicolas Apfel ^{b} , Sara Khalid ^{c} , Timothy
5	M Frayling ^{a,d} , and Jack Bowden ^{a} , on behalf of the GEMINI Consortium
6	$^a\mathrm{Genetics}$ of Complex Traits, Exeter Medical School, University of Exeter, Exeter, UK
7	$^b\mathrm{Department}$ of Economics, University of Southampton, Southampton, UK
8	$^{c}\mathrm{Centre}$ for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and
9	Musculoskeletal Sciences, University of Oxford, Oxford, UK
10	$^d\mathrm{Faculty}$ of Medicine, Department of Genetic Medicine and Development, CMU, Geneva,
11	Switzerland
	November 7, 2023
12	*correspondence: x.liang2@exeter.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

13

Abstract

Mendelian randomization (MR) is an epidemiological approach that utilizes genetic 14 variants as instrumental variables to estimate the causal effect of a modifiable but 15 likely confounded exposure on a health outcome. This paper investigates an MR 16 scenario in which different subsets of genetic variants identify different causal ef-17 fects. These variants may aggregate into clusters, and such variant clusters are 18 likely to emerge if they affect the exposure and outcome via distinct biological 19 pathways. In the framework of multi-outcome MR, where a common risk factor 20 causally impacts several disease outcomes simultaneously, these variant clusters 21 can reflect the heterogeneous effects this shared risk factor concurrently exerts 22 on all the diseases under examination. This, in turn, can provide insights into 23 the disease-causing mechanisms underpinning the co-occurrence of multiple long-24 term conditions, a phenomenon known as multimorbidity. To identify such variant 25 clusters, we adapt the general method of Agglomerative Hierarchical Clustering 26 (AHC) to the summary data MR setting, enabling cluster detection based on the 27 variant-specific causal estimates, using only genome-wide summary statistics. In 28 particular, we tailor the method for multi-outcome MR to aid the elucidation of 29 the potentially multifaceted causal pathways underlying multimorbidity stemming 30 from a shared risk factor. We show in various Monte Carlo simulations that our 31 'MR-AHC' method detects variant clusters with high accuracy, outperforming the 32 existing multi-dimensional clustering methods. In an application example, we use 33 the method to analyze the causal effects of high body fat percentage on a pair 34 of well-known multimorbid conditions, type 2 diabetes (T2D) and osteoarthritis 35 (OA), discovering distinct variant clusters reflecting heterogeneous causal effects. 36 Pathway analyses of these variant clusters indicate interconnected cellular processes 37 underlying the co-occurrence of T2D and OA; while the protective effect of higher 38 39 adiposity on T2D could possibly be linked to the enhanced activity of ion channels 40 related to insulin secretion.

Keywords: Mendelian randomization; clustering analysis; multimorbidity; robust
 MR; hierarchical clustering; heterogeneous causal effects.

43 Introduction

Mendelian randomization (MR) is a widely used method in epidemiology that leverages 44 genetic variants (usually in the form of single nucleotide polymorphisms, SNPs) as in-45 strumental variables (IV) for estimating the causal effect of a potentially confounded 46 exposure on an outcome [1, 2]. If a genetic variant is sufficiently associated with the 47 exposure, independent of possible confounders of the exposure-outcome relationship, and 48 affects the outcome only through the exposure, then it is a valid instrument for assess-49 ing causality [3]. With further parametric assumptions, for example that relationships 50 between all variables are additive and linear, and all variants included as instruments 51 encode a single homogeneous causal effect from the exposure to the outcome, then the 52 causal parameter of interest can be estimated using simple meta-analytic methods based 53 on genome-wide summary statistics [4–6]. In this setting, all the variant-specific causal 54 estimates are expected to target the same, true causal effect, and their 'ratio' estimates 55 (derived as the ratio of the variant-outcome to variant-exposure association), from which 56 the overall meta-analysis is performed, should vary by sampling error alone [7, 8]. Excess 57 'heterogeneity' amongst the ratio estimates is therefore a sign that one or more of the 58 assumptions has been violated [9]. 59

60

A major source of excess heterogeneity is undoubtedly *horizontal pleiotropy*, the phe-61 nomenon whereby a variant affects multiple traits and therefore is associated with the 62 outcome through pathways other than via the exposure [9, 10]. This has been extensively 63 studied with improved methods for pleiotropy detection [8, 11] and robust estimation [5, 64 12, 13]. Violation of the causal effect homogeneity assumption, has, by contrast, been far 65 less researched, despite this being a plausible feature of many analyses. For example, it is 66 suspected that general adiposity, which is often proxied by a single trait like body mass 67 index (BMI), exerts a heterogeneous causal effect on type 2 diabetes (T2D) depending 68 on the location of the adipose tissue in the body (e.g. if it is peripheral or visceral) [14]. 69 In this case, variants associated with different physiological aspects of the exposure may 70

⁷¹ target distinct causal effects.

72

In the presence of excess heterogeneity from both sources, the genetic variants can be 73 grouped into distinct clusters, such that all variants in each cluster indicate the same 74 effect. Several studies have explored variant clusters in the MR framework. It is well 75 recognized that it is impossible to discern whether each cluster embodies genuine causal 76 mechanisms between the exposure and outcome, or is formed due to pleiotropic pathways, 77 without further domain knowledge or modelling assumptions. Therefore, overdispersion 78 caused by both sources can be summarized under an umbrella term such as "clustered 79 heterogeneity", as proposed by Foley et al. [15], or "mechanistic heterogeneity" by Iong 80 et al. [16]. 81

82

In this paper, we propose a method to identify variant clusters under mechanistic hetero-83 geneity, building upon the Agglomerative Hierarchical Clustering (AHC) method devel-84 oped by Apfel and Liang [17] in the field of econometrics for IV selection. We adapt the 85 method to the summary-data MR setting, hence referring to it as "MR-AHC", to group 86 variants based on their ratio estimates using genome-wide summary statistics. More no-87 tably, we have tailored the method to the multi-outcome MR setting, in which a shared 88 exposure causally impacts several disease outcomes simultaneously. This extension is 89 specially crafted for investigating the causal mechanisms underpinning multimorbidity, 90 which refers to the co-existence of two or more long-term conditions in one individual [18]. 91 92

A substantial and growing proportion of the adult population is affected by multimorbidity, and it has been recognized as a global priority for health research [19, 20]. It is therefore important to comprehend the underlying disease-causing pathways. Numerous studies have identified common risk factors associated with a broad range of conditions. New methods have also been introduced for identifying these factors [21]. However, such shared risk factors are often complex traits and may exert heterogeneous influences on diseases through multifaceted mechanisms. For example, obesity, one of the most

well-established risk factors contributing to various forms of multimorbidity [22, 23], is recognized to impact diseases through a variety of distinct pathways [14, 24].

102

Given the multitude of potential causal pathways stemming from a common risk fac-103 tor, particularly in the case of complex traits like obesity, to enable effective clinical 104 prevention and intervention, it is necessary to elucidate the mechanisms through which 105 this common risk factor induces the co-occurrence of the conditions. A starting point can 106 be identifying the variant clusters associated with diverse causal effects within a multi-107 outcome MR framework. To illustrate this, consider the hypothetical example depicted 108 in Figure 1. Here, variants linked to the exposure X are divided into three groups (G_1 to 109 G_3), as they influence the two disease outcomes Y_1 and Y_2 through three different aspects 110 of the exposure X (denoted by X_1 to X_3) that might not be easy to measure directly. 111 Among the three groups, G_1 is associated with an increasing effect on Y_1 but a protective 112 effect against Y_2 , and G_3 indicates an increasing effect on Y_2 but no effect on Y_1 . Only 113 the group G_2 corresponds to pathways through which the shared risk factor increases the 114 risk of both diseases. Therefore, identifying variant clusters can unveil the potentially 115 heterogeneous causal effects, and subsequently shed light on the mechanisms linking the 116 common risk factor to the co-occurrence of the conditions.



Figure 1: Left: Multi-outcome MR involving two disease outcomes and a common risk factor; right: clusters formed by the variants associated with the common exposure, which reflect heterogeneous causal pathways.

117

Several clustering approaches have been proposed within the MR framework to group ge-118 netic variants based on their causal estimates, such as MR-Clust [15] and MR-PATH [16]. 119 However, these methods are primarily tailored to settings involving a single exposure and 120 a single outcome, making them less suitable for handling the complexities of multimor-121 bidity, as they lack multi-dimensional clustering options. On the other hand, methods 122 such as NAvMix [25] do allow for multi-dimensional clustering of genetic variants, but 123 are not inherently rooted in the MR framework, since they group variants based on their 124 direct variant-trait associations, rather than causal estimates. This may limit their utility 125 for causal inference. The mclust method [26] does permit multi-dimensional clustering 126 using causal estimates, but we show that the method's accuracy can be sub-optimal. In 127 contrast, our MR-AHC method allows for multi-dimensional causal clustering based on 128 MR estimates, whilst achieving a high clustering accuracy, which we have demonstrated 129 in extensive Monte Carlo simulations. 130

131

We apply MR-AHC to investigate the causal effects of body fat percentage (BFP), as 132 a shared risk factor, on a pair of multimorbid conditions, T2D and osteoarthritis (OA). 133 Our analysis identifies four variant clusters indicating heterogeneous effects on both con-134 ditions. To provide insights into the underlying causal pathways, we conducted com-135 prehensive gene-set analyses on the clusters, combining evidence from both canonical 136 pathway analyses and gene-set Phenome-wide association analyses (PheWAS). While the 137 clustering results cannot directly label a cluster as signifying genuine mechanisms or 138 pleiotropic pathways, we show how post-clustering analyses may enable this distinction. 139 Our findings on the cluster associated with increasing risks of both conditions indicate 140 shared pathways underpinning the co-occurrence of T2D and OA through interconnected 141 cellular processes related to gene expression transcription and cellular responses to stim-142 uli. We provide further evidence using cluster-specific MR for the unifying pathway from 143 obesity to the T2D-OA multimorbidity through elevated oxidative stress. Another cluster 144 exhibits a protective effect against T2D, with integrated canonical pathway and PheWAS 145 evidence supporting a possible mechanism involving enhanced activity of the ion chan-146

nels related to insulin secretion. This might be linked to elevated levels of high-density
lipoprotein cholesterol (HDL-C) associated with smaller waist-to-hip ratios.

149 Results

¹⁵⁰ The MR-AHC method for clustering genetic variants in summary-

¹⁵¹ data Mendelian randomization

We assume the following summary statistics for J genetic variants involved in an MR 152 investigation: the variant-exposure association estimate $\hat{\gamma}_j$, and the variant-outcome as-153 sociation estimate $\widehat{\Gamma}_{j}$, where j = 1, ..., J. In an MR setting with a common exposure and 154 multiple P outcomes, $\widehat{\boldsymbol{\Gamma}}_{\boldsymbol{j}}$ is the vector of the P variant-outcome associations. We main-155 tain the assumption that the variant-exposure associations are measured from a sample 156 independent from all the variant-outcome association samples, but overlap between the 157 outcome samples is allowed. We also assume that all the genetic variants are themselves 158 mutually uncorrelated (i.e. not in linkage disequilibrium). The causal estimates of the 159 exposure on the P outcomes using only variant j as instrument (i.e. the ratio estimates) 160 can then be obtained as the *P*-dimensional vector $\hat{\beta}_j = \hat{\Gamma}_j / \hat{\gamma}_j$. Let $\hat{\Sigma}_j$ be an estimate of 161 the covariance matrix of $\hat{\beta}_j$. 162

163

We propose MR-AHC, a two-step procedure with $\left\{ \hat{\beta}_{j}, \hat{\Sigma}_{j} \right\}_{i=1}^{J}$ as inputs, to group genetic 164 variants indicating the same causal effects, or in other words, having similar observed ratio 165 estimates $\hat{\beta}_j$, into the same cluster. We illustrated the method with a simple hypothetical 166 example, shown in Figure 2. For ease of illustration, we consider the case with a single 167 outcome, but the same procedure applies generally with multiple outcomes. The first 168 step of the method, the merging step, is illustrated in the left panel of Figure 2. It shows 169 a situation with six variants that form three clusters (one of them comprised of a single 170 variant). The dotted lines at β_1 and β_2 are the true heterogeneous causal effects from the 171 exposure to the outcome, and the circles above the real line denote the variant-specific ra-172 tio estimates. The differences in the size of the circles reflect the fact that summary data 173

estimates exhibit varying degrees of uncertainty. In the explanation below, we refer to these estimates and their corresponding variants by the numbers 1 to 6, from left to right.

In the initialization step of the merging process (Step 0 in the illustration), each variantspecific estimate has its own cluster. Next, we merge the two estimates which are closest in terms of their weighted squared Euclidean distance, i.e. those estimated with Variant 3 and 4 (the two red circles). These two estimates are merged into one cluster and we now have five clusters left. We re-calculate the pairwise distances with the five clusters and merge the closest two into a new cluster. We continue with this procedure until step 5 where all variants are in a single cluster.



Figure 2: Illustration of the MR-AHC method for a hypothetical example adapted from Apfel and Liang [17]. Left panel: Ward's algorithm defines a clustering path. Right panel: A downward testing procedure is applied until the step-specific heterogeneity statistics can not be rejected at a specified threshold.

By the end of the merging step, we have generated a clustering path. Along each step of 184 the path, the number of clusters, denoted by \mathcal{K} , varies from $\mathcal{K} = 1$ to $\mathcal{K} = J$ by incre-185 ments of 1. Next, in the second step of MR-AHC, we re-trace the clustering path to select 186 the optimal value of \mathcal{K} using a downward testing procedure, operates as follows: starting 187 from the largest cluster containing all variants, apply Cochran's Q test [27] to examine 188 the degree of heterogeneity of all the ratio estimates by calculating the test statistic and 189 comparing it with a pre-specified significance threshold. If the null hypothesis of "no ex-190 cess heterogeneity" gets rejected, then move to the next level of the clustering path and 191 apply the Q test to all the sub-clusters on that level. We repeat this process until reach-192

¹⁹³ ing a level where no sub-cluster heterogeneity statistic rejects at the given significance ¹⁹⁴ threshold. In our illustrative example, we would expect the downward testing procedure ¹⁹⁵ to re-trace from step 5 to step 3 of the clustering path, thus determining three groups ¹⁹⁶ formed by Variants 1-2, Variants 3-5, and Variant 6 alone.

197

In the original AHC algorithm proposed by Apfel and Liang [17], the inputs are essen-198 tially just the ratio estimates $\hat{\beta}_{j}$, hence the clustering objects are treated as non-random 199 fixed data points. MR-AHC adjusts the algorithm to take into account the uncertainty 200 of $\hat{\beta}_j$ by incorporating the covariance matrix $\hat{\Sigma}_j$ into the weighted squared Euclidean 201 distance in the merging process. We show in Appendix A that this distance between two 202 clusters is essentially the Wald statistic for testing the null hypothesis that "the two clus-203 ters indicate the same causal effect". Therefore, merging two clusters with the smallest 204 distance can be interpreted as merging two clusters with the highest similarity in their 205 cluster-specific causal effects. 206

207

In terms of the covariance matrix estimate $\widehat{\Sigma}_{j}$, we show in Appendix A that if all the 208 outcome samples are non-overlapping and/or the phenotypic correlations between the 209 outcome traits are zero, then all the ratio estimates of a given variant are uncorrelated. 210 In this case, all the covariance terms are zero and $\hat{\Sigma}_{j}$ is just a diagonal matrix with the 211 non-zero entries being the variances of the ratio estimates, which can be easily estimated 212 from the GWAS summary statistics. If the covariances are non-zero, we show that $\hat{\Sigma}_j$ 213 can be estimated via linkage disequilibrium (LD) score regression [28] and seamlessly 214 incorporated into the analysis. 215

216

In the downward testing procedure, following the recommendation in Belloni et al. [29], we define the threshold p-value for the Q test as $\zeta = 0.1/\log(n)$ where n is the sample size. We prove in Appendix B that this threshold p-value results in a consistent clustering procedure. That is, as n increases, the probability of correctly identifying all true members of each cluster tends to 1. If the exposure and outcome samples are of different

sizes, we recommend using the sample size of the smallest outcome sample. For binary outcomes, an effective sample size can be approximated with the number of cases and controls, see Han and Eskin [30].

225

MR-AHC does not require pre-specification of the number of clusters. It can also easily 226 identify a "null cluster" and a "junk cluster", following the terminology of Foley et al. 227 [15], which refer to, respectively, the cluster identifying a zero causal effect, and the clus-228 ter containing variants not assigned to any detected clusters. Specifically, we conduct a 229 post-clustering Wald test on each cluster-specific causal estimate for the null hypothesis 230 of a zero causal effect using $\zeta = 0.1/\log(n)$ as the threshold significance p-value. For the 231 junk cluster, we simply classify all variants that do not fit into any other clusters as junk 232 variants. To further improve the clustering accuracy of MR-AHC, we also extend the 233 basic algorithm illustrated above to an outlier-robust version, to correct for the outliers 234 in the ratio estimates, see the method section for details. 235

236 Simulation results

We conduct Monte Carlo simulations to evaluate the performance of the MR-AHC 237 method in detecting variant clusters and estimating the causal effects in various settings 238 that mimic the multimorbidity scenarios we are interested in, which involve a shared 239 exposure causally affecting multiple outcome conditions. We consider 12 simulation de-240 signs, where the number of outcomes is either P = 2 or P = 3, the number of substantive 241 variant clusters is either K = 1 or K = 4, and the sample correlation between the out-242 comes is either $\rho = 0$, $\rho = 0.2$ or $\rho = 0.7$ (see the method section for a detailed definition 243 of ρ). In all designs, we have J = 100 SNPs with 10 designated as true 'junk' variants. 244 245

The two classes of scenarios stratified by the number of variant clusters are illustrated in Figure 3. The directed acyclic graph (DAG) in Panel (a) illustrates the data generation process when there are four substantive clusters and one noise cluster. Multiple outcomes (two or three) are represented by the single notation Y. Variant clusters are formed due

to differential sub-components of the exposure, denoted by X_1 to X_5 . Variant Cluster 1 250 and X_1 represent a correlated pleiotropy pathway, and Clusters 2 to 4 correspond to gen-251 uine heterogeneous causal mechanisms from the exposure to the outcomes. The scatter 252 plot on the right of Panel (a) is based on a representative simulated dataset of the two-253 outcome case. We also examine the performance of the method when there is actually no 254 mechanistic heterogeneity, i.e. there is only one real cluster and one noise cluster. The 255 design is shown by a DAG and representative dataset in Figure 3 Panel (b). The arrow 256 from X_1 to Y is absent, meaning that the only substantive cluster is also a null cluster 257 and there is no causal effect between the exposure and the outcomes. See the method 258 section for a detailed design specification. 259

260

We compare MR-AHC with two other multi-dimensional clustering approaches. The 261 first is the mclust algorithm [26], a general clustering method that accommodates the 262 utilization of ratio estimates as inputs. We select this method as it is one of the most 263 widely used clustering method based on Gaussian mixture models [26]. We implement 264 mclust in two ways: the basic setting without a noise component, and the setting incor-265 porating a Poisson noise component. An initial value of the proportion of noise variants 266 is required, and we set this value favourably as 10% which is the ground truth. The 267 second method, NAvMix, proposed by Grant et al. [25], groups genetic variants based 268 on the variant-trait associations instead of the ratio estimates. We choose this method 269 for comparison as it is also motivated by elucidating the biological mechanisms that can 270 possibly be revealed by the patterns of the genetic variants associated with various traits. 271 We employed two sets of input data for NAvMix: the variant-trait associations, as ini-272 tially proposed; and the ratio estimates as in MR-AHC. Similar to mclust, we set the 273 initial proportion of noise variants for NAvMix at 10%. For these two methods, cluster 274 membership is assigned based on the highest probability. As a general clustering method 275 for mechanistic heterogeneity, MR-AHC also works in the one-outcome case. We com-276 pare MR-AHC with MR-Clust [15], a popular method for conducting one-dimensional 277 clustering based on ratio estimates, see Table S4 in Appendix D. 278



(a) Simulation designs with 4 substantive variant clusters.



(b) Simulation designs with 1 substantive variant cluster.

Figure 3: Directed acyclic graphs (DAG) of the data generation process and scatter plots of representative simulated data (with two outcomes) of the simulation designs with different numbers of variant clusters.

We report the following statistics from the simulations for each approach: the number of 279 substantive clusters detected by the methods ("#clusters"); the Rand index which mea-280 sures the similarity between the true clustering structure and the detected clusters for the 281 substantives clusters ("Rand index"); the number of variants classified into the junk clus-282 ter ("#junk variants"); the number of true noise variants classified by the methods as junk 283 ("correct junk"); the mean absolute error ("MAE") and the mean squared error ("MSE"). 284 For simulation designs with one substantive cluster indicating zero causal effects, we 285

additionally report the frequency of correctly identifying the null cluster ("*Freq.null*").
Definitions of the statistics can be found in the method section.

288

For scenarios involving non-zero outcome sample correlations, since the GWAS results 289 typically lack a direct estimate for the correlation, we initially apply all methods treating 290 the correlation ρ as zero. The two-outcome simulation results are presented in Figure 4 291 and Table 1. Across all settings, MR-AHC consistently demonstrates high accuracy in 292 identifying the number of clusters, aligning closely with the ground truth in both mean 293 and median assessments. In the boxplot of MR-AHC (Panel (a) of Figure 4), all the 294 quantiles are concentrated around the median, showing that the method consistently di-295 vides variants into the correct number of clusters with little fluctuation. By comparison, 296 both settings of mclust tend to underestimate the number of clusters when there are four 297 true clusters and overestimate it when only one substantive cluster exists. The NAvMix 298 method, employing two different sets of input, also exhibits a tendency to underestimate 299 the number of clusters when K = 4. While it successfully identifies one cluster when 300 K = 1 with low outcome correlations, it overestimates the cluster number when the out-301 come correlation is high ($\rho = 0.7$). In line with the cluster number results, MR-AHC 302 performs very well in terms of grouping the variants correctly, as measured by the Rand 303 index. It consistently achieves Rand indices close to 1, significantly outperforming all 304 other approaches in all settings. One potential drawback of MR-AHC is its tendency 305 to assign slightly more noise variants to the "junk" cluster than the true count, but the 306 number of true noise variants selected as junk of MR-AHC is only marginally lower than 307 that of mclust with the noise component, outperforming all other approaches. Regarding 308 estimation bias, both MR-AHC and NAvMix with ratio estimates input exhibit compara-309 ble MAE and MSE in general, both of which are smaller than those of other methods in 310 most of the settings. For scenarios where K = 1, MR-AHC accurately identifies the null 311 cluster with frequencies close to 1. The two variations of NAvMix also exhibit high accu-312 racy in this aspect, although this accuracy diminishes for NAvMix with ratio estimates 313 when the outcome correlation is high. 314



Panel (a) – The number of detected substantive clusters.

Panel (b) – Rand index for variants in the substantive clusters.



Figure 4: Two outcomes – boxplots for the number of detected substantive clusters and Rand index with different cluster numbers (K = 4 or K = 1) and outcome correlations ($\rho = 0, \rho = 0.2$ and $\rho = 0.7$). All methods are conducted treating the outcome correlations as 0. The dotted horizontal lines represent the true values. "*mclust noise*" stands for the mclust algorithm with a noise component, and "*NAvMix ratio*" for the NAvMix method with ratio estimates as input. Results are based on 1000 replications.

Table 1: Simulation results for designs with two outcomes. All methods are conducted treating the outcome correlations as 0. "mclust noise" stands for the mclust algorithm with a noise component, and "NAvMix ratio" for the NAvMix method with ratio estimates as input. Statistics are calculated as the mean over 1000 replications.

	MR-AHC	mclust	mclust noise	NAvMix	NAvMix ratio	
Two outcomes, K	$= 4, \mathrm{correc}$	elation =	= 0			
# clusters	4.196	3.716	2.964	3.018	2.307	
Rand index	0.917	0.757	0.737	0.615	0.710	
# junk variants	10.966	0.000	7.726	6.517	4.080	
# correct junk	6.975	0.000	7.134	1.446	3.951	
MAE	0.088	0.120	0.123	0.162	0.106	
MSE	0.030	0.041	0.041	0.052	0.035	
Two outcomes, $K = 4$, correlation = 0.2						
# clusters	4.207	3.665	2.933	3.130	2.254	
Rand index	0.915	0.744	0.725	0.630	0.694	
# junk variants	10.916	0.000	7.835	6.930	3.999	
# correct junk	7.031	0.000	7.234	1.493	3.906	
MAE	0.088	0.118	0.122	0.153	0.101	
MSE	0.030	0.039	0.040	0.048	0.032	
Two outcomes, K	= 4, corre	elation =	= 0.7			
# clusters	4.229	3.652	3.754	3.649	2.202	
Rand index	0.918	0.784	0.835	0.684	0.677	
# junk variants	10.993	0.000	8.044	5.347	3.925	
# correct junk	7.144	0.000	7.433	1.302	3.844	
MAE	0.089	0.091	0.088	0.119	0.087	
MSE	0.029	0.027	0.027	0.035	0.024	
Two outcomes, K	= 1, corre	elation =	= 0			
# clusters	1.026	2.211	1.312	1.000	1.001	
Rand index	0.947	0.887	0.895	0.818	0.818	
# junk variants	10.194	0.000	8.211	0.000	0.000	
# correct junk	7.703	0.000	7.073	0.000	0.000	
MAE	0.012	0.020	0.015	0.017	0.017	
MSE	0.000	0.020	0.010	0.000	0.000	
Freq.null	0.955	0.726	0.767	0.998	0.997	
Two outcomes $K = 1$ correlation = 0.2						
# clusters	1 019	2.226	1 297	1 009	1 007	
π clusters Rand index	0.949	0.881	0.803	0.816	0.816	
# junk variants	10.275	0.001	8 438	0.010	0.010	
# correct junk	7 833	0.000	7 199	0.009	0.008	
π correct junk MAE	0.012	0.000	0.015	0.005	0.000	
MSE	0.012	0.021 0.004	0.015	0.017	0.010	
Freq null	0.000	0.004 0.724	0.791	0.000	0.001	
	0.303 - 1	0.124	0.151	0.330	0.550	
Two outcomes, $K = 1$, correlation = 0.7						
# clusters	1.023	2.221	1.290	1.005	1.001	
Rand Index	0.948	0.910	0.924	0.340	0.040	
# JUNK variants	9.085	0.000	9.458	29.057 E 000	27.930 E 000	
# correct junk	1.990	0.000	0.020	0.099	0.020 0.119	
MAE	0.013	0.019	0.014	0.020	0.113	
MDE Englisher 11	0.000	0.003	0.001	0.001	0.015	
Freq.null	0.954	0.760	0.785	0.928	0.102	

When K = 4 with non-zero outcome correlations, MR-AHC tends to identify more clus-315 ters than the ground truth. This feature can be rectified by incorporating accurate 316 outcome correlation information, see the results generated by applying the method with 317 the true correlation parameter (Table S2 in Appendix D). We show in Appendix A that 318 the outcome correlation depends on both the extent of sample overlap between the out-319 come samples, and the phenotypic correlation between the outcome traits. Hence, high 320 outcome correlations are uncommon in practice. To achieve, for instance, a correlation 321 of $\rho = 0.7$, one would need perfect sample overlap and a phenotypic correlation of 0.7 322 between the two outcome traits. Even in this extreme scenario, implementing MR-AHC 323 while assuming a zero correlation performs reasonably well. The simulation results for 324 scenarios with three outcomes are presented in Appendix D, Table S1 and S3. Once again, 325 MR-AHC exhibits good performance, producing clustering results that closely align with 326 the ground truth and generally surpassing the performance of all other approaches. 327

Estimating the causal effects of higher adiposity on type 2 dia betes and osteoarthritis

We apply the MR-AHC method to investigate the causal relationship between body fat percentage (BFP), as a measure of adiposity, and a pair of multimorbid conditions, T2D and OA. We use a three-sample summary-data MR design with 487 SNPs associated with BFP as instruments, accounting for the causal effects of the common risk factor BFP on both of the conditions simultaneously. For comparison, we also perform variant clustering using the mclust algorithm and the NAvMix method.

336

The clustering results of MR-AHC are presented in Figure 5, Panel (a). It detects 4 substantive clusters indicating heterogeneous causal effects. The cluster-specific estimation results, obtained with the inverse-variance weighted (IVW) approach [5], are depicted in Figure 5, Panel (b). Among the 4 clusters, Cluster 1 with 124 SNPs is the only cluster associated with increasing risk for both conditions; Cluster 2 with 258 SNPs indicates an increasing risk for T2D but a null effect for OA; both Cluster 3 (32 SNPs) and Cluster 4

³⁴³ (22 SNPs) are associated with a protective effect against T2D, and for OA, a causative

effect and a null effect, respectively. See Appendix E for detailed estimation results.

Panel (a) - (left) The scatter plot of the 487 SNPs associated with BFP; On the x-axis are the ratio estimates for T2D, and y-axis for OA. Each point represents a specific SNP. (right) the clustering results of MR-AHC.



Panel (b) – The cluster-specific IVW estimates and 95% confidence intervals in odds ratio for each cluster detected by MR-AHC.



Figure 5: MR-AHC clustering and estimation results of the 487 SNPs associated with BFP based on their ratio estimates on T2D and OA.

These results align with the conclusions drawn from previous research. For example, Mar-345 tin et al. [24] examined the causal effects of higher adiposity on a variety of conditions 346 including T2D and OA. Their findings suggest that adiposity exerts heterogeneous effects 347 on the risk of T2D: in general, higher adiposity increases the risk of T2D, but there is a 348 metabolically "favourable" component of adiposity that reduces the risk of the condition. 349 For OA, all adiposity measures, including the metabolically favourable adiposity, consis-350 tently identify an increasing risk. This suggests a non-metabolic weight-bearing effect as 351 a likely cause. Given this, it is reasonable to partition the variants into distinct clusters 352 along both outcome dimensions: on the T2D-estimate dimension, clustering occurs due 353 to the indication of opposing effects by different variants; on the OA-estimate dimension, 354 clustering is also likely to occur, as we may expect an adverse effect if the variants are 355 associated with fat located around the articulations in a load-bearing way, but no effect 356 elsewhere. 357

358

The clustering results generated with mclust and NAvMix are presented in Figure 6. 359 Both methods fail to segregate the variants along the OA-estimate dimension, as all clus-360 ters indicate increasing effects, hence might have underestimated the number of clusters, 361 which also appears as an over-arching feature of the methods in the simulations. Even 362 for the T2D-estimate clustering, their results may be dubious: mclust assigns SNPs in 363 nonadjacent regions with largely opposing estimates into the same cluster (Cluster 2 in 364 blue); NAvMix either labels a large number of SNPs as 'junk' if setting a non-zero initial 365 noise proportion, or does not identify any noise at all with a zero initial proportion. More 366 importantly, for clusters generated by these two methods, variants tend to display sub-367 stantial within-cluster heterogeneity in their ratio estimates, which can be a significant 368 concern for causal inference. 369



Figure 6: From left to right: the clustering results of the mclust algorithm with an initial noise proportion 5%; the clustering results of the NAvMix method with an initial noise proportion 0; the clustering results of the NAvMix method with an initial noise proportion 5%.

³⁷⁰ Biological insights into the variant clusters

To gain insights into the biological mechanisms linking obesity to the T2D-OA multi-371 morbidity from the variant clusters detected by MR-AHC, we use an approach similar 372 to the one taken by previous works such as Grant et al. [25] and Wang et al. [31]. For 373 each of the clusters identified by MR-AHC, we first map the SNPs in the cluster to genes, 374 then perform gene set enrichment analysis with the mapped genes. Both steps are con-375 ducted using the Functional Mapping and Annotation Platform (FUMA) [32]. SNPs are 376 mapped to genes using a three-way mapping strategy (positional, eQTL and chromatin 377 interactions mapping). The gene set enrichment analysis is to test if the mapped genes 378 are over-represented in a given pre-defined gene set which corresponds to a canonical 379 biological pathway or is associated with a phenotype reported from the GWAS catalog. 380 We refer to the latter as the gene-set Phenome-wide association analysis (PheWAS), or 381 just "PheWAS" for short. We integrate both lines of evidence from the pathway and Phe-382 WAS analyses that can complement or validate each other, to infer the possible biological 383 mechanisms underlying each cluster. See Supplementary material S2 for a summary of 384

³⁸⁵ the enrichment analyses results.

386

First, it is likely that Cluster 2 (containing 258 SNPs, associated with increasing risk of T2D) is highly pleiotropic. Based on the PheWAS analysis, this cluster is enriched with a large number of phenotypes, double that for Cluster 1 which has the second most (112 versus 56). These phenotypes fall into a wide range of categories, displaying no clear pattern. The majority of the canonical pathways enriched for this cluster are related to intermediate filament, which might not have a strong direct link with the causal relationship under examination.

394

Cluster 1 (containing 124 SNPs, indicating increasing risks of both conditions) holds 395 particular significance as it aligns with our primary objective of exploring the multimor-396 bidity of T2D and OA through obesity. The majority of the canonical pathways uniquely 397 enriched for Cluster 1 can be classified into two categories of cellular processes that are 398 closely interconnected: gene expression transcription and cellular responses to stimuli. A 399 significant example in the first category is DNA methylation, while in the second cate-400 gory, one of the most significantly enriched pathways is associated with oxidative stress. 401 For some of the pathways, we can delve deeper into the investigation using readily avail-402 able GWAS data. As an example, we further inspect the possible unifying pathway from 403 obesity to the T2D-OA multimorbidity via oxidative stress. 404

405

Oxidative stress (OS) is the imbalance between the production of reactive oxygen species 406 and the counteracting antioxidant defenses in the direction that favors the former, which 407 may lead to tissue injury [33]. Clinical research has established that obesity can induce 408 systemic OS through various metabolic pathways [34, 35]. Moreover, OS is evidenced 409 to exert direct effects on the development of T2D via mechanisms such as decreasing 410 insulin secretion from pancreatic β cells [36, 37]. It also plays a role in the progression 411 of OA by promoting cartilage degradation [38]. Herein, we examine the role of OS by 412 performing cluster-specific MR: we first analyze how BFP predicted by SNPs in cluster 413

⁴¹⁴ 1 is associated with a variety of OS biomarkers. Then for comparison, we conduct the
⁴¹⁵ same analysis on Cluster 4, serving as a counterpart to Cluster 1 due to its relatively
⁴¹⁶ benign nature for both conditions, manifesting a protective effect against T2D and a null
⁴¹⁷ effect on OA.

418

We select 11 OS biomarkers from diverse categories. First, as endogenous antioxidants 419 are highly responsive to OS [39], we use 4 enzyme antioxidants (GST, CAT, SOD, GPX) 420 as OS injury biomarkers, which have been utilized in previous MR studies [40, 41]. One of 421 the mechanisms through which obesity induces systemic OS is chronic inflammation [34, 422 35]. We thus incorporate three traits known to mediate the pathway from inflammation 423 to OS (CRP, IL-6, TNF- α) [35] as another set of OS biomarkers. Biochemical research 424 has shown that the production of some cytokines, including IL-1 β , IL-12 and IL-8, are 425 enhanced under elevated OS levels [42, 43]. Therefore, we also include these three cy-426 tokines in the analysis. Finally, we incorporate GDF-15, which is a biomarker for both 427 inflammation and OS [44]. See the method section for the full form of the abbreviations 428 of the biomarkers. 429

430

We estimate the effect of BFP on each of the biomarkers by two-sample MR using SNPs 431 in Cluster 1 and Cluster 4 as instruments separately. The estimates and standard errors 432 are calculated by the IVW approach. Sensitivity checks by MR-PRESSO [45] and the ro-433 bust adjusted profile score (MR-RAPS) method [13] can be found in Appendix E. Results 434 in Z-scores are presented in Figure 7. For 8 out of 11 of these OS markers, Cluster 1 is 435 associated with increasing effects, while Cluster 4 is associated with declining effects. For 436 CAT and CRP, Cluster 1 and Cluster 4 have effects in the same direction, but Cluster 1 437 is either associated with a larger increasing effect (CRP), or a smaller decreasing effect 438 (CAT). The only exception is SOD, on which the increasing effect of Cluster 1 is smaller 439 than that of Cluster 4. 440

441

442 Overall, we can see a clear heterogeneity pattern between Cluster 1 and Cluster 4 in

their cluster-specific effects on the OS biomarkers, which supports that Cluster 1 is associated with an elevated level of oxidative stress, while it may be the opposite for Cluster 445 4. These results align with the existing findings regarding adiposity and oxidative stress: higher adiposity is in general associated with elevated oxidative stress, but fat patterns featured with a smaller waist-to-hip ratio (WHR) may be related to less oxidative damage [35, 46]. This correlation between WHR and OS is observed in Cluster 4, as we will show later that this cluster is associated with a decreasing WHR.





Figure 7: Results of the two-sample MR estimating the effects of BFP on the 11 oxidative stress biomarkers and 2 psychological disorders using variants in Cluster 1 and Cluster 4 as instruments respectively. Estimates are given by the IVW approach, presented in the form of Z-scores (the ratio of the estimate and the standard error). "*" represents significance at the p-value 0.05; "**" for the first 11 traits represents significance at 0.05/11, for the last two traits at 0.05/2.

Complementary evidence that may be related to the shared pathway via oxidative stress 451 can be found in the PheWAS results for Cluster 1. A notable PheWAS pattern associated 452 with this cluster is that it is enriched with quite a few psychological disorders. Clinical 453 research has shown that OS is implicated in the development of such disorders, including 454 bipolar disorder and depression [47], which are both significantly enriched for Cluster 1. 455 We estimate the effects of BFP predicted by variants in respectively Cluster 1 and Cluster 456 4 on bipolar and major depressive disorder (MDD) using two-sample MR. Results are 457 presented in the last two columns in Figure 7. Cluster 1 is associated with increasing 458 risks of both conditions with a significant effect on bipolar. The effects of Cluster 4, on 459 the other hand, are both insignificant and smaller than those of Cluster 1. These results 460 may suggest a possible direction for exploring the multimorbidity between obesity-related 461 metabolic conditions and psychological disorders. 462

463

It is important to note that there is very likely to be intricate interactions between the 464 pathways involved in the underlying mechanism from obesity to the T2D-OA multimor-465 bidity. For example, another canonical pathway uniquely enriched for Cluster 1 is related 466 to programmed cell death, or apoptosis. It has been well-documented that excess OS 467 plays a role in the activation of apoptosis [48], and pancreatic β -cell and chondrocyte loss 468 due to apoptosis are implicated in the development of T2D and OA respectively [49, 50]. 469 Furthermore, quite a few gene expression transcription pathways enriched for Cluster 1 470 are related to epigenetic processes. Emerging evidence supports the involvement of OS 471 in epigenetic regulation of gene expression such as inducing DNA methylation changes 472 [51, 52]. Thus, additional research is warranted to further unravel the exact causal roles 473 of these pathways. 474

475

Both Cluster 3 and Cluster 4 exhibit a protective effect against T2D. The most noteworthy PheWAS pattern for these two clusters is that they are both enriched with phenotypes related to fat distribution. This is particularly pronounced for Cluster 4, with 17 out of 479 42 enriched phenotypes associated with fat patterns including the WHR-related traits. 480 Also, Cluster 4 has a clear pattern regarding its enriched biological pathways: 13 out 481 of 16 of the pathways are related to ion channel activities. Ion channels are membrane 482 proteins acting as gated pathways for the passage of ions across the cell membranes [53].

To integrate the evidence from the WHR-enriched PheWAS pattern and the ion-channel-484 enriched pathway pattern into a potential explanation of the protective mechanism against 485 T2D, one possible link may be that Cluster 4 is also enriched with several HDL-C related 486 phenotypes. Existing studies have found a negative relationship between WHR and HDL-487 C [54, 55], i.e. smaller WHR may be associated with higher levels of HDL-C. Moreover, 488 the connection between HDL-C levels, ion channel activities, and T2D development might 489 be explained by the primary role of HDL-C in cholesterol clearance [56]. On one hand, 490 ion channels, such as the β -cell voltage-gated calcium channels, are crucial for insulin 491

secretion [57]. On the other hand, the activity of such channels can be suppressed by excess membrane cholesterol [29]. Thus, the depletion of cholesterol facilitated by HDL-C might positively impact the activity of the ion channels related to insulin secretion. This link is evidenced by previous experimental research on mice, which shows that reduced HDL-C levels are correlated with impaired glucose-induced insulin secretion [58]. This is because the increased rigidity of the β -cell membrane due to cholesterol-enrichment reduces the stimulation of ion channels essential for secreting insulin [59, 60].

499

To examine the possible protective mechanism against T2D stated above, we conduct two-sample MR to examine the effects indicated by Cluster 4 on WHR (adjusted for BMI), HDL-C and total cholesterol levels. The results, shown in Figure 8, are in line with the hypothesized mechanism: this cluster is associated smaller WHRs, higher levels of HDL-C, lower levels of total cholesterol, and consequently decreasing risk of coronary artery disease (CAD).



Figure 8: Two-sample MR results estimating the effects of cluster 4-predicted BFP on the waistto-hip ratio adjusted for BMI, HDL-C, total cholesterol and coronary artery disease. Estimates are given by the IVW approach, presented in the form of the 95% confidence intervals.

506 Discussion

In this paper we adapt the general method of agglomerative hierarchical clustering to the summary-data Mendelian randomization setup. MR-AHC is a useful tool for interrogating a set of genetic variants to see if they collectively identify a single causal effect, or if it is more plausible that a number of subgroups identify distinct effects driven by different biological mechanisms. The method is of particular interest when the potentially

⁵¹² heterogeneous physiological components of the exposure are not known beforehand, or
⁵¹³ are difficult/expensive to measure. Of special interest is its utility as a multi-dimensional
⁵¹⁴ clustering method in the multi-outcome MR setting, where we can elucidate the shared
⁵¹⁵ causal pathways that underlie the co-occurrence of a range of conditions through a com⁵¹⁶ mon risk factor.

517

In an effort to investigate the intricate mechanisms underpinning disease causation, a 518 number of approaches has been utilized to categorize genetic variants associated with 519 a specific phenotype, based on their GWAS associations with a range of traits linked 520 to that target phenotype, such as the Bayesian nonnegative matrix factorization clus-521 tering method [61] and the NAvMix method [25]. MR-AHC is motivated similarly by 522 the purpose of exploring the diverse disease-causing pathways reflected by distinct vari-523 ant clusters. However, it is distinctly tailored to a different scenario and employs a 524 different clustering strategy. Its primary application is rooted in the domain of causal 525 inference, specifically within the framework of MR. It groups genetic variants based on 526 their causal estimates, which integrates both their associations with the target pheno-527 type (in this context, a common exposure) and their associations with the related traits 528 (herein, downstream outcomes). By the comparison with NAvMix through Monte Carlo 529 simulations and the real-world application, we have shown that MR-AHC has certain 530 advantages over the association-based approaches in MR settings, namely an enhanced 531 capacity to identify the patterns of the genetic variants that may mirror distinct causal 532 mechanisms between specific traits. Furthermore, while the variant clusters discovered 533 through association-based methods may have broad biological implications encompassing 534 a wide range of traits, those detected by MR-AHC are precisely focused on elucidating a 535 specific causal relationship. Consequently, pathway information derived from each cluster 536 identified by MR-AHC offers a higher degree of relevance and specificity for the causal 537 relationship under examination. 538

539

540 MR-AHC possesses the features that it does not require pre-specifying the number of

clusters, and that alongside detecting meaningful clusters it can also identify and label 541 null and junk clusters without an initial specification on the proportion of 'noise'. While 542 for hierarchical clustering algorithms, it can be difficult to choose the 'optimal' dissimilar-543 ity metric, linkage and number of clusters on the dendrogram to yield reliable clustering 544 results, studies in the field of model selection [17, 62] provide the theoretical basis for 545 MR-AHC to ensure highly accurate results. We have adapted the original AHC method 546 in Apfel and Liang [17] to accommodate the varying degrees of uncertainty exhibited in 547 summary-data estimates due to allele frequency differences across SNPs. Moreover, our 548 method is capable of handling outliers in the variant-specific estimates with our outlier 549 removal procedure. It should be noted that all the aforementioned methods assign vari-550 ants to clusters in a probabilistic (i.e. 'soft') way, while MR-AHC do the clustering in 551 a deterministic (i.e. 'hard') manner. Although we view this as a strength, some may 552 view its lack of stochasticity as a disadvantage. For this reason we plan to develop a 553 framework to quantify the sensitivity of MR-AHC clustering results to small changes in 554 the data and thresholding rule used. 555

556

We showed in simulations that, in situations of sample overlap in the outcome data, 557 incorporating the correct correlation information can improve the performance of the 558 method. Nevertheless, it is in general not a significant concern if the correlation esti-559 mates are set to zero. Our method is currently focused on the problem of estimating a 560 causal relationship between the shared exposure and the downstream outcomes without 561 accounting for the direct causality between the outcomes. In our application example, 562 various existing evidence supports the absence of direct causality between T2D and OA 563 [63, 64]. However, we show in Appendix C that even if direct causality exists, our method 564 is still applicable, as the clustering of the variants associated with the common exposure 565 are generally robust to the outcome causality. The challenge then shifts to estimating 566 the direct causal effect of the exposure on a particular outcome while considering other 567 outcome traits as an additional risk factor, or accepting that the original estimates repre-568 sent total causal effects via the outcome in question. Given this, another potential future 569

extension of our work is to extend the method to the multi-exposure framework, with the additional flexibility to consider genetic sub-structure within each exposure.

572 Materials and Methods

573 Model setup

We start from the individual-level model underlying the variant-exposure and variant-574 outcome summary associations. We assume a general linear IV model for the MR frame-575 work allowing for multiple outcomes with a shared exposure, which accounts for pleiotropy 576 and heterogeneous causal mechanisms. We also assume that the causal effects from the 577 exposure to the outcomes via different pathways are additive. Therefore, without loss 578 of generality, we model the causality heterogeneity using additive sub-components of the 579 exposure. Let the common exposure X be denoted by $X = X_1 + \dots + X_k$ where X_k 580 is the k-th sub-component in X and k = 1, ..., K. Let the p-th observed outcome be 581 denoted by the scalar Y_p where p = 1, ..., P and $P \ge 2$ in a multi-outcome MR. The 582 vector $\mathbf{G} = (G_1, ..., G_J)'$ is used to denote the J genetic variants used as instruments. 583 We then have the following linear structural model: 584

$$U = \sum_{j=1}^{J} \eta_j G_j + \epsilon_U, \tag{1}$$

$$X_k = \sum_{j=1}^J \delta_{kj} G_j + q_{xk} U + \epsilon_{Xk}, \qquad (2)$$

$$X = \sum_{k=1}^{K} X_k, \tag{3}$$

$$Y_p = \sum_{k=1}^{K} \theta_{kp} X_k + \sum_{j=1}^{J} \psi_{jp} G_j + q_{yp} U + \epsilon_{Yp}, \qquad (4)$$

585 where

• U represents the uncontrolled confounding between Y_p and any sub-component of X, with the strength of confounding determined by parameters q_{xk} and q_{yp} ;

• $\epsilon_U, \epsilon_{Xk}$ and ϵ_{Yp} are error terms affecting U, X_k and Y respectively, and we assume $E(\epsilon_U G_j) = E(\epsilon_{Xk} G_j) = 0$ for all j = 1, ... J;

• $\theta_{1p}, ..., \theta_{Kp}$ represent the heterogeneous causal effects of X on Y_p .

⁵⁹¹ We maintain the assumption that all the variants are independent with each other, and ⁵⁹² therefore inspect the relationship between each individual variant G_j and X as well as ⁵⁹³ between G_j and Y_p . First, from (1) and (2), we obtain the reduced-form relationship ⁵⁹⁴ between X_k and G_j as

$$X_k = \gamma_{kj} G_j + \xi_{Xkj},$$

where the total effect of G_j on X_k is $\gamma_{kj} = \delta_{kj} + q_{xk}\eta_j$. The error term ξ_{Xkj} is defined implicitly, but from the the previous assumptions $E(\epsilon_U G_j) = E(\epsilon_{Xk} G_j) = 0$ and that G_j is independent with all other variants, we have $E(\xi_{Xkj}G_j) = 0$ as well. It follows from (3) that the overall relationship between G_j and the exposure X is

$$X = \gamma_j G_j + \xi_{Xj} \tag{5}$$

599 where

$$\gamma_j = \sum_{k=1}^{K} \gamma_{kj} = \sum_{k=1}^{K} \delta_{kj} + \eta_j \sum_{k=1}^{K} q_{xk},$$
(6)

and the error term $\xi_{Xj} = \sum_{k=1}^{K} \xi_{Xkj}$ with $E(\xi_{Xj}G_j) = 0$. We assume that the relevance condition for the instruments is satisfied at the scale of the overall exposure X so that $\gamma_j \neq 0$ for j = 1, ..., J.

603

Now we inspect the reduced-relationship between G_j and Y_p . It follows from (4) that the pleiotropic effect of G_j on Y_p can be derived as $\alpha_{jp} = \psi_{jp} + q_{yp}\eta_j$. Additionally by plugging (1) and (2) into (4), the overall reduced-form between Y_p and G_j is

$$Y_p = \Gamma_{jp}G_j + \xi_{Ypj},\tag{7}$$

607 where

$$\Gamma_{jp} = \sum_{k=1}^{K} \theta_{kp} \gamma_{kj} + \alpha_{jp} = \sum_{k=1}^{K} \theta_{kp} \delta_{kj} + \eta_j (\sum_{k=1}^{K} \theta_{kp} q_{xk} + q_{yp}) + \psi_{jp}.$$
(8)

The correlation between the implicitly-defined error term ξ_{Ypj} and G_j depends on the correlation between ϵ_{Yp} from Equation 4 and G_j . If $E(\epsilon_{Yp}G_j) = 0$, then ξ_{Ypj} and G_j are also uncorrelated. In this case, for the G_j - Y_p association estimate (denoted by $\hat{\Gamma}_{jp}$) generated from a GWAS by regressing Y_p on G_j in a given sample, we have

$$\widehat{\Gamma}_{jp} \xrightarrow{p} \Gamma_{jp}$$

as the sample size $n \to \infty$. Similarly, for the G_j -X association estimated in a GWAS (denoted by $\hat{\gamma}_j$) in a sample independent from the G_j - Y_p sample, we have

$$\widehat{\gamma}_j \xrightarrow{p} \gamma_j$$

as $n \to \infty$. Then for the variant-specific causal estimate of G_j , defined as $\hat{\beta}_{jp} = \hat{\Gamma}_{jp}/\hat{\gamma}_j$, we have

$$\hat{\beta}_{jp} \xrightarrow{p} \beta_{jp}$$
 and $\beta_{jp} = \frac{\Gamma_{jp}}{\gamma_j} = \frac{\sum_{k=1}^{K} \theta_{kp} \gamma_{kj} + \alpha_{jp}}{\sum_{k=1}^{K} \gamma_{kj}}.$

In words, as the sample size n goes to infinity, each $\hat{\beta}_{jp}$ converges to their variant-specific causal estimand β_{jp} , which is the causal effect from X to Y_p identified using G_j as instrument. In the simple case where G_j only instruments one sub-component X_k , the variant-specific causal estimand then becomes:

$$\beta_{jp} = \frac{\theta_{kp}\gamma_{kj} + \alpha_{jp}}{\gamma_{kj}} = \theta_{kp} + \frac{\alpha_{jp}}{\gamma_{kj}}.$$
(9)

Equation 9 reflects the possible sources of mechanistic heterogeneity among the variantspecific estimates: heterogeneous causal effect from the exposure to the outcome, and pleiotropic effects. We aim to group the genetic variants into distinct clusters such that within each cluster, all variants identify the same causal effect. More generally, for the

multi-outcome MR with $P \geq 2$ outcomes, with a given variant G_j , we combine all $\hat{\beta}_{jp}$ and β_{jp} for p = 1, ..., P into the vectors $\hat{\beta}_j = (\hat{\beta}_{j1}, ..., \hat{\beta}_{jP})'$ and $\beta_j = (\beta_{j1}, ..., \beta_{jP})'$ respectively. We propose the MR-AHC method, elaborated in the subsequent section, to divide the genetic variants into distinct clusters based on the similarity of their ratio estimates $\hat{\beta}_j$, so that variants with the same estimand β_j are in the same cluster.

Thus far, we have inspected the case where there is no residual correlation between 630 G_j and ϵ_{Yp} in Equation 4, i.e. $E(\epsilon_{Yp}G_j) = 0$. In a multi-outcome MR model, this rela-631 tionship can be violated if there is direct causality between the outcome variables. For 632 example, consider two outcomes Y_p and Y_q , if Y_q causally affects Y_p directly, then it will 633 enter Equation 4 as part of ϵ_{Yp} , hence the error term may be correlated with G_j . We 634 show in Appendix C that the clustering results of the variants are in general not affected 635 by the additional direct causality between the outcomes, but the causal effects identified 636 by each cluster are the total effects including the outcomes causality, instead of the direct 637 effects from the exposure to the outcomes. In this paper, we mainly focus on the case 638 without the direct outcome causality. 639

640 The MR-AHC algorithm

We make the following normality assumption on the summary statistics described in 641 the previous section: $\sqrt{n} \left(\begin{pmatrix} \hat{\Gamma}_{jp} \\ \hat{\gamma}_j \end{pmatrix} - \begin{pmatrix} \Gamma_{jp} \\ \gamma_j \end{pmatrix} \right) \xrightarrow{d} N \left(\begin{pmatrix} 0 \\ 0 \end{pmatrix}, \begin{pmatrix} \sigma_{Yjp}^2 & 0 \\ 0 & \sigma_{Yj}^2 \end{pmatrix} \right)$, for 642 j = 1, ..., J and p = 1, ..., P. It follows that $\sqrt{n} \left(\widehat{\beta}_{jp} - \beta_{jp} \right) \xrightarrow{d} N \left(0, \sigma_{jp}^2 \right)$. The estimates 643 of the standard errors of $\hat{\gamma}_j$ and $\hat{\Gamma}_{jp}$, denoted by $se(\hat{\gamma}_j)$ and $se(\hat{\Gamma}_{jp})$, are generally given 644 by the corresponding GWAS, hence taken as known. The standard error of $\hat{\beta}_{jp} = \hat{\Gamma}_{jp}/\hat{\gamma}_j$ can then be obtained using the Delta method as $\hat{v}_{jp} = \sqrt{\frac{se(\hat{\Gamma}_{jp})^2 + \hat{\beta}_{jp}^2 se(\hat{\gamma}_j)^2}{\hat{\gamma}_j^2}}$. But it is 645 646 typically approximated by $\hat{v}_{jp} = se\left(\widehat{\Gamma}_{jp}\right)/|\widehat{\gamma}_j|$ since $se\left(\widehat{\gamma}_j\right)$ is deemed negligible when 647 we only use variants that pass a genome-wide significance threshold as instruments [11]. 648 When there are multiple outcomes, let $\hat{\Sigma}_{j}$ be the estimate of the covariance matrix of 649 $\hat{\boldsymbol{\beta}}_{\boldsymbol{j}}$. The diagonal entries of $\hat{\boldsymbol{\Sigma}}_{\boldsymbol{j}}$ are just the variances of $(\hat{\beta}_{j1}, ..., \hat{\beta}_{jP})'$, i.e. $(\hat{v}_{j1}^2, ..., \hat{v}_{jP}^2)'$. 650

The off-diagonal entries of $\hat{\Sigma}_{j}$ are the pairwise covariances of $(\hat{\beta}_{j1}, ..., \hat{\beta}_{jP})'$. We show in Appendix A that the covariances are zero if the outcome samples are non-overlapping and/or the phenotypic correlations between the outcome traits are zero, otherwise, they can be estimated using LD score regression [28].

655

With the summary statistics $\{\hat{\beta}_{j}, \hat{\Sigma}_{j}\}_{j=1}^{J}$ as inputs, we apply MR-AHC to discover the variant clusters using a two-step procedure: Step 1 (agglomerative hierarchical clustering) generates a decision path from $\mathcal{K} = J$ to $\mathcal{K} = 1$ clusters; Step 2 (downward testing) re-traces the path from $\mathcal{K} = 1$ to $\mathcal{K} = J$ until the optimal cluster choice \mathcal{K}_{opt} is chosen. The first step is summarized as follows:

661 Step 1. Ward's algorithm [65]

⁶⁶² 1. Initialization: Each variant-specific estimate is viewed as a cluster on its own. ⁶⁶³ Hence, initially, the total number of clusters is $\mathcal{K} = J$.

2. Merging: The two clusters that are closest as measured by their weighted squared Euclidean distance are merged into a new cluster. Without loss of generality, assume this is satisfied by cluster S_k and S_l . $\hat{\beta}_{S_k}^{IVW}$ is defined as the inverse-variance weighted mean of all the variant-specific estimates in S_k , as follows:

$$\widehat{\boldsymbol{\beta}}_{\boldsymbol{\mathcal{S}}_{\boldsymbol{k}}}^{IVW} = \left(\widehat{\beta}_{\boldsymbol{\mathcal{S}}_{k},1}^{IVW}, ..., \widehat{\beta}_{\boldsymbol{\mathcal{S}}_{k},P}^{IVW}\right)'$$

668 where

$$\widehat{\beta}_{\mathcal{S}_k,p}^{IVW} = \frac{\sum_{j \in S_k} \widehat{\beta}_{jp} w_{jp}}{\sum_{j \in S_k} w_{jp}}$$
(10)

with $w_{jp} = 1/v_{jp}^2$ for p = 1, ..., P. $\hat{\beta}_{S_l}^{IVW}$ for Cluster S_l can be defined similarly. Then the weighted squared Euclidean distance between S_k and S_l is defined as

$$\mathcal{D}_{k,l} = \left(\widehat{\boldsymbol{\beta}}_{\boldsymbol{\mathcal{S}}_{\boldsymbol{k}}}^{IVW} - \widehat{\boldsymbol{\beta}}_{\boldsymbol{\mathcal{S}}_{\boldsymbol{l}}}^{IVW}\right)' \widehat{\boldsymbol{\Omega}}_{k,l}^{-1} \left(\widehat{\boldsymbol{\beta}}_{\boldsymbol{\mathcal{S}}_{\boldsymbol{k}}}^{IVW} - \widehat{\boldsymbol{\beta}}_{\boldsymbol{\mathcal{S}}_{\boldsymbol{l}}}^{IVW}\right).$$
(11)

671 The $P \times P$ matrix $\widehat{\Omega}_{k,l}$ is defined as follows: let $W_{kp} = \sum_{j \in S_k} w_{jp}$, and $W_{lp} = \sum_{j \in S_l} w_{jp}$ for p = 1, ..., P. Consider the entry at the *i*-th column and the *r*-th row

of
$$\widehat{\Omega}_{k,l}$$
 with $i, r \in \{1, ..., P\}$, denoted by cov_{ir} . We have

$$cov_{ir} = \frac{\rho_{ir}}{W_{ki}W_{kr}} \sum_{j \in S_k} \frac{\widehat{\gamma}_j^2}{se\left(\widehat{\Gamma}_{ji}\right)se\left(\widehat{\Gamma}_{jr}\right)} + \frac{\rho_{ir}}{W_{li}W_{lr}} \sum_{j \in S_l} \frac{\widehat{\gamma}_j^2}{se\left(\widehat{\Gamma}_{ji}\right)se\left(\widehat{\Gamma}_{jr}\right)},$$

674

where ρ_{ir} is the correlation between $\widehat{\Gamma}_{ji}$ and $\widehat{\Gamma}_{jr}$, which is assumed to be constant across j = 1, ..., J. See Appendix A for details. 675

3. Iteration: The merging step is repeated until all the variant-specific estimates are 676 in one cluster of size J. 677

After generating the clustering path using Step 1, we are left with a $\mathcal{K} = 1$ super-cluster 678 containing all variants. We then re-trace the pathway to select the optimal value of \mathcal{K} 679 using a downward testing procedure originally proposed by Andrews [62], operating as 680 follows: 681

- Step 2. Downward testing procedure. 682
- 683

Firstly, define Q_{fg} to be the Cochran's Q statistic [27] associated with the g-th cluster at 684 level f of the clustering path, denoted by S_{fg} . Also define T_{fg} to be the $(1-\zeta)$ significance 685 threshold of a χ^2 distribution on $P \times (|\mathcal{S}_{fg}| - 1)$ degrees of freedom with $\zeta = 0.1/\log(n)$, 686 n is the sample size, and $|S_{fg}|$ is the number of variants in S_{fg} . Q_{fg} is defined as follows: 687 for the p-th outcome, let $\hat{\beta}^p$ be the vector of length $|S_{fq}|$ with the j-th entry being $\hat{\beta}_{jp}$ 688 where $j \in S_{fq}$. Combine all $\hat{\beta}^{p}$ into a vector of length $P \times |S_{fq}|$ for all p = 1, ..., P, 689 denoted by \mathcal{B}_{fg} . Let $\hat{\beta}^{p}_{IVW}$ be the IVW mean of all the estimates in $\hat{\beta}^{p}$ as defined in (10), 690 and ι be a vector of 1 of length $|\mathcal{S}_{fg}|$. Then combine all the $|\mathcal{S}_{fg}|$ -length vector $\iota \widehat{\beta}_{IVW}^p$ 691 into a vector of length $P \times |\mathcal{S}_{fg}|$ for all p = 1, ..., P, denoted by \mathcal{B}_{fg}^{IVW} . Then Q_{fg} is 692

$$Q_{fg} = \left(\mathcal{B}_{fg} - \mathcal{B}_{fg}^{IVW}\right)' \widehat{\Phi}_{fg}^{-1} \left(\mathcal{B}_{fg} - \mathcal{B}_{fg}^{IVW}\right), \qquad (12)$$

where $\widehat{\Phi}_{fg}$ is a matrix that can be partitioned into $P \times P$ blocks. The block on the *i*-th 693 column and r-th row, denoted by $\hat{\phi}_{ir}$, is a $|\mathcal{S}_{fg}| \times |\mathcal{S}_{fg}|$ dimension diagonal matrix. The 694 *j*-the diagonal entry equals to $\frac{\rho_{ir}se(\widehat{\Gamma}_{ji})se(\widehat{\Gamma}_{jr})}{\gamma_i^2}$ for $j \in S_{fg}$. 695

⁶⁹⁶ 1. Starting from the cluster that contains all the variants, calculate the global Q statis-⁶⁹⁷ tic, Q_{11} , on all the ratio estimates;

- ⁶⁹⁸ 2. If $Q_{11} < T_{11}$, then stop and assume that all the variants form a single cluster. If ⁶⁹⁹ $Q_{11} \ge T_{11}$, then revert to the variant clusters on the next level of the path, where ⁷⁰⁰ the number of clusters is $\mathcal{K}=2$;
- ⁷⁰¹ 3. Calculate Q statistics for the two sub-clusters separately, Q_{21} and Q_{22} ;
- 4. If both $Q_{21} < T_{21}$ and $Q_{22} < T_{22}$, then stop. Otherwise, continue to the next level where $\mathcal{K}=3$;
- 5. Repeat steps 3-4 until a $\mathcal{K} \in (1, ..., J)$ is arrived at for which no sub-cluster heterogeneity statistic rejects at its given threshold.

In implementing the MR-AHC method, in addition to the baseline procedure summarized 706 in Step 1 and 2, we propose an extension of the method to handle outliers in the ratio 707 estimates: after we run Step 1 and 2 and obtain the clustering results, within each 708 detected cluster, calculate each individual variant's contribution to the overall Q statistic. 709 The individual Q statistic, calculated using (12) with only estimates of that variant, 710 approximately follows a χ^2_P distribution [11], and variants with large individual Q (here 711 defined as the p-value of the individual Q below 5%) are viewed as outliers. We remove 712 the outliers from each detected cluster, and re-run Step 1 and 2 with all the remaining 713 variants. All the outliers are then assigned to the junk cluster. 714

715 Monte Carlo simulations

For all the simulation designs, we simulate two/three-sample summary data based on the data generating process defined in Model (1)-(4) with all sample sizes equal to N =60,000. Here we fix $\psi_j = 0$. We assume that G_j , X and Y_p are normalized with $Var(G_j) =$ $Var(X) = Var(Y_p) = 1$ and $\mathbb{E}[G_j] = \mathbb{E}[X] = \mathbb{E}[Y_p] = 0$. We also assume that the covariances between the variants are 0, $Cov(G_j, G_i) = 0$ for $i \neq j$. According to Equation

(6) and (8), the variant-exposure and variant-outcome summary statistics are generated
in the following way:

$$\widehat{\beta}_{Xj} = \sum_{k=1}^{K} \delta_{kj} + \eta_j \sum_{k=1}^{K} q_{xk} + N(0, 1/N),$$
$$\widehat{\beta}_{Yjp} = \sum_{k=1}^{K} \theta_{kp} \delta_{kj} + \eta_j (\sum_{k=1}^{K} \theta_{kp} q_{xk} + q_{yp}) + e_{Ypj},$$

for j = 1, ..., J with J = 100 and p = 1, 2 or p = 1, 2, 3. The normally distributed random 723 variables N(0, 1/N) add the random component to $\hat{\beta}_{Xj}$ that mimics the asymptotically 724 normal distribution of the statistics obtained from GWAS with standardized data. The 725 random error of $\hat{\beta}_{Yjp}$, denoted by e_{Ypj} , is generated from a multivariate normal distri-726 bution for the multiple outcomes. All the variance terms of this multivariate normal 727 distribution are set to 1/N. When there are P = 2 outcomes, the covariance equals 728 ρ/N with $\rho = 0, 0.2, \text{ and } 0.7$ for the zero, low, and high outcome correlation settings 729 respectively. When there are P = 3 outcomes, the pair-wise outcome correlation equals 730 to $\rho_{ij} = \rho^{|i-j|}$ where $i, j \in \{1, 2, 3\}$ and $i \neq j$ with $\rho = 0, 0.2$ and 0.7 for three different 731 settings. Then the standard errors of $\hat{\beta}_{Xj}$ and $\hat{\beta}_{Yjp}$ are given by 732

$$se(\hat{\beta}_{Xj}) = se(\hat{\beta}_{Yjp}) = \sqrt{1/N}$$

To simulate the summary statistics, we need to set the values of the following parameters: θ_{kp} (the causal effect of the sub-component X_k on Y_p), δ_{kj} (the effect of variant G_j on X_k), η_j (the effect of variant G_j on the uncontrolled confounder U), and q_{xk} , q_{yp} (the effect of U on X_k and Y_p respectively). Let the variation in U explained by all the variants θ_U^2 , and the variation in X_k directly explained by all the variants (not through U) be h_U^2 . Then given the values of h_U^2 and h_k^2 , parameters θ_{kp} , q_{xk} and q_{yp} are set as constants under the following restrictions to make $Var(X) = Var(Y_p) = 1$ feasible:

$$\sum_{k=1}^{K} h_k^2 + h_U^2 \sum_{k=1}^{K} q_{xk}^2 < 1, \qquad \sum_{k=1}^{K} \theta_{kp}^2 h_k^2 + h_U^2 \sum_{k=1}^{K} q_{xk}^2 \theta_{kp}^2 + q_y^2 h_U^2 < 1$$

When there are K = 4 substantive clusters (with 15, 15, 30, 30 variants respectively) and 740 one noise cluster (with 10 variants), let $h_U^2 = 0.05$ and $h_k^2 = (0, 0.05, 0.1, 0.1, 0.005)$ for 741 k = 1, ..., 5 with the last entry for the junk cluster. Set $q_{xk} = 1$ for the first cluster, which 742 corresponds to the correlated pleiotropy pathway, and $q_{xk} = 0$ for all the other clusters. 743 When there are two outcomes, let $q_{y1} = 0.4$ and $q_{y2} = 0.1$. The causal effect parame-744 ters are set as $\theta_{k1} = (0.1, 0.3, 0.5, 0.4)$ for the first outcome, and $\theta_{k2} = (0.2, -0.3, 0.6, 0)$ 745 for the second outcome, with k = 1, ..., 4. Causal effects of the 10 noise variants are 746 generated from N(0,1). When there are three outcomes, additionally set $q_{y3} = 0.2$ and 747 $\theta_{k3} = (-0.2, 0.3, 0, 0.3).$ 748

749

756

When there is K = 1 substantive cluster (with 90 variants) and one noise cluster (with 10 variants), set $h_U^2 = q_{xk} = q_{yp} = 0$ and $h_k^2 = (0.1, 0.005)$. The causal effects of X on all the outcomes are set to zero. In all simulation designs, δ_{kj} and η_j are generated from the uniform distribution U[0.1, 0.3], and are randomly assigned to be positive or negative, then re-scaled as $\delta_{kj}\sqrt{h_k^2}/\sqrt{\sum_{j=1}^J \delta_{kj}^2}$ and $\eta_j\sqrt{h_U^2}/\sqrt{\sum_{j=1}^J \eta_j^2}$ to make sure that variations in U and X_k explained by the variants equal to h_u^2 and h_k^2 respectively.

The Rand index [66] is a quantity which measures the similarity between two clustering 757 outcomes with values between 0 and 1. It is given by $R = (a+b)/\binom{p}{2}$. Here, a denotes 758 the number of pairs of objects that are classified as belonging to the same cluster in both 759 clustering outcomes and b is the number of pairs of objects that are classified in different 760 clusters by both clustering outcomes. R values close to 1 indicate good agreement and 761 values close to 0 indicate poor agreement between two clustering outcomes. Here the 762 Rand index is calculated with variants assigned to the substantive clusters by the meth-763 ods. The mean absolute error (MAE) and mean squared error (MSE) are calculated as 764 follows: 765

$$MAE_{p} = \frac{1}{J'} \sum_{j=1}^{J'} |\beta_{jk} - \hat{\beta}_{jk}|, \quad MSE_{p} = \frac{1}{J'} \sum_{j=1}^{J'} (\beta_{jk} - \hat{\beta}_{jk})^{2},$$

where J' is the number of variants that are not assigned to the junk cluster by the meth-766 ods, and do not belong to the junk cluster by the ground truth. β_{ik} is the true causal 767 effect associated with the cluster which G_j truly belongs to, and $\hat{\beta}_{jk}$ is the causal esti-768 mate associated with the cluster which G_j is assigned to by the methods. The subscript 769 p denotes the p-th outcome, and the overall MAE and MSE are calculated as means over 770 all the outcomes. 771

772

MR-AHC is performed with the outlier-robust variation as described previously. To avoid 773 spurious clusters, we only report the detected clusters containing more than 4 variants. 774 Small clusters with less than 4 variants are subsumed into the junk cluster. The inputs 775 for NAvMix are standardized before being supplied to the algorithm, as recommended 776 in Grant et al. [25]. The cluster-specific causal estimates are obtained using the IVW 777 approach. One exception is that if there is overdispersion within a detected cluster, as 778 indicated by a non-zero I^2 , then the cluster-specific estimate and its standard error are 779 calculated using MR-RAPS [13] to account for the within-cluster overdispersion. 780

Clustering analysis on the BFP associated genetic variants based 781 on the causal estimates of T2D and OA 782

We use SNP-BFP summary data from a GWAS study based on UK Biobank individuals 783 from Martin et al. [24], including 696 SNPs at genome-wide significance $(p < 5 \times 10^{-8})$. 784 The T2D GWAS statistics are from Mahajan et al. [67], which combine 31 published 785 GWAS studies but exclude the UK Biobank individuals. The SNP-OA summary statis-786 tics are from a FinnGen GWAS (code: M13 ARTHROSIS INCLAVO) [68]. Only SNPs 787 present in all three datasets are used for analyses (487 in total). SNPs are orientated 788 across all three datasets in the direction of increasing the exposure. The T2D and OA 789

⁷⁹⁰ samples are non-overlapping, therefore for each SNP, the covariance between the SNP⁷⁹¹ T2D estimate and SNP-OA estimate is treated as zero.

792

In implementing the MR-AHC method, we use the effective sample size [30] of the T2D 793 GWAS sample (n = 193, 440) to calculate the threshold p-value $0.1/\log(n)$ in the binary 794 outcome setting for Cochran's Q test and the post-selection Wald test in detecting the 795 null clusters. Clustering results of MR-AHC are obtained using an iterated outlier re-796 moval procedure: this performs the outlier removal and re-fitting indefinitely until the 797 individual p-values of the Q statistics for all SNPs are above 5%. The cluster-specific 798 causal estimates and standard errors are calculated with the IVW approach. For clusters 799 with overdispersion indicated by a non-zero I^2 , the estimates are obtained using MR-800 RAPS to account for the within-cluster overdispersion. We set the initial proportion of 801 noise SNPs as 5% for both mclust and NAvMix. 802

⁸⁰³ Post-clustering analysis

We map SNPs in each cluster to genes using the SNP2GENE function in FUMA based 804 on positional mapping (with deleterious coding SNPs) [69], eQTL mapping, and chro-805 matin interaction mapping. This three-way mapping strategy is used in the applied 806 examples in the original paper introducing FUMA [32]. The uploaded SNPs are also 807 set to be the pre-defined lead SNPs. All default settings are applied, with the excep-808 tion that we set the reference panel population as "UKB release2b 10k European". For 809 eQTL mapping, following the practice in Grant et al. [25], we select tissue types from the 810 following data sources: eQTL catalogue, PsychENCODE, van der Wijst et al. scRNA 811 eQTLs, DICE, eQTLGen, Blood eQTLs, MuTHER, xQTLServer, ComminMind Consor-812 tium, BRAINEAC and GTEx v8 [70–79]. For chromatin interaction mapping, we select 813 all available Hi-C datasets. The gene-set enrichment analysis is conducted using the 814 GENE2FUNC function in FUMA. For the mapped genes corresponding to each cluster, 815 we perform the hypergeometric test to check if the mapped genes are over-represented 816 in a pre-defined gene set. Multi-testing correction with the Benjamini-Hochberg proce-817

dure is applied, with the adjusted p-value ≤ 0.05 as threshold [32]. The pre-defined gene sets for canonical pathways and gene ontology processes are obtained from MsigDB and WikiPathways [80, 81]. Gene sets for phenotypes are from GWAS catalog [82].

821

To test how the variant clusters are associated with oxidative stress, we create a list 822 of 11 OS biomarkers from various categories, including: glutathione transferase (GST), 823 catalase(CAT), superoxide dismutase(SOD), glutathione peroxidase (GPX), C-reactive 824 protein (CRP), Interleukin 6 (IL-6), Tumor necrosis factor alpha (TNF- α), Interleukin 825 1 beta (IL-1 β), Interleukin 12 (IL-12), Interleukin 8 (IL-8) and Growth/differentiation 826 factor-15 (GDF-15). The GWAS summary statistics for the four antioxidants (GST, CAT, 827 SOD, GPX) and CRP are obtained from the GWAS of Sun et al. [83]; for GDF-15, the 828 GWAS of Gudjonsson et al. [84]; for the rest five cytokines, the GWAS of Ahola-Olli et al. 829 [85] and Kalaoja et al. [86]. Summary statistics for bipolar disorder and major depres-830 sion disorder are taken from two GWAS studies conducted by the Psychiatric Genomics 831 Consortium [87, 88]. For MR analyses associated with Cluster 4, the WHR (adjust for 832 BMI) statistics are obtained from a GWAS conducted by the GIANT Consortium [89]; 833 for the HDL-C and total cholesterol data, the GWAS from the Global Lipids Genetics 834 Consortium [90]; for CAD, the GWAS from the CARDIoGRAMplusC4D Consortium 835 [91]. 836

References

- [1] George Davey Smith and Shah Ebrahim. "Mendelian randomization: prospects,
 potentials, and limitations". In: *International journal of epidemiology* 33.1 (2004),
 pp. 30-42.
- [2] Debbie A Lawlor et al. "Mendelian randomization: using genes as instruments for
 making causal inferences in epidemiology". In: *Statistics in medicine* 27.8 (2008),
 pp. 1133–1163.
- [3] Vanessa Didelez and Nuala Sheehan. "Mendelian randomization as an instrumental variable approach to causal inference". In: *Statistical methods in medical research* 16.4 (2007), pp. 309–330.
- [4] Tom M Palmer et al. "Using multiple genetic variants as instrumental variables
 for modifiable risk factors". In: *Statistical methods in medical research* 21.3 (2012),
 pp. 223-242.

Jack Bowden and Michael V. Holmes. "Meta-analysis and Mendelian randomiza-|5|850 tion: A review". In: Research Synthesis Methods 10.4 (2019), pp. 486–496. DOI: 851 https://doi.org/10.1002/jrsm.1346. URL: https://onlinelibrary.wiley. 852 com/doi/abs/10.1002/jrsm.1346. 853

- Patrick MA Sleiman and Struan FA Grant. "Mendelian randomization in the era of [6]854 genomewide association studies". In: *Clinical chemistry* 56.5 (2010), pp. 723–728. 855
- Miguel A Hernán and James M Robins. "Instruments for causal inference: an epi-|7|856 demiologist's dream?" In: Epidemiology (2006), pp. 360–372. 857
- Fabiola Del Greco M et al. "Detecting pleiotropy in Mendelian randomisation stud-8 858 ies with summary data and a continuous outcome". In: Statistics in medicine 34.21 859 (2015), pp. 2926–2940. 860
- Stephen Burgess et al. "Guidelines for performing Mendelian randomization inves-[9] 861 tigations: update for summer 2023". In: Wellcome open research 4 (2019). 862
- Gibran Hemani, Jack Bowden, and George Davey Smith. "Evaluating the potential [10]863 role of pleiotropy in Mendelian randomization studies". In: Human Molecular Ge-864 netics 27.R2 (May 2018), R195–R208. ISSN: 0964-6906. DOI: 10.1093/hmg/ddy163. 865 URL: https://doi.org/10.1093/hmg/ddy163. 866
- [11]Jack Bowden et al. "Improving the accuracy of two-sample summary-data Mendelian 867 randomization: moving beyond the NOME assumption". In: International Journal 868 of Epidemiology 48.3 (Dec. 2018), pp. 728–742. ISSN: 0300-5771. DOI: 10.1093/ 869 ije/dyy258. URL: https://doi.org/10.1093/ije/dyy258. 870
- Jack Bowden et al. "A framework for the investigation of pleiotropy in two-sample |12|871 summary data Mendelian randomization". In: Statistics in medicine 36.11 (2017), 872 pp. 1783–1802. 873
- [13]Qingyuan Zhao et al. "Statistical inference in two-sample summary-data Mendelian 874 randomization using robust adjusted profile score". In: The Annals of Statistics 48.3 875 (2020), pp. 1742–1769. 876
- Ruth JF Loos and Tuomas O Kilpeläinen. "Genes that make you fat, but keep you [14]877 healthy". In: Journal of internal medicine 284.5 (2018), pp. 450–463. 878
- Christopher N Foley et al. "MR-Clust: clustering of genetic variants in Mendelian 15 879 randomization with similar causal estimates". In: Bioinformatics 37.4 (2021), pp. 531-880 541. 881
- Daniel Iong, Qingyuan Zhao, and Yang Chen. "A latent mixture model for het-[16]882 erogeneous causal mechanisms in Mendelian randomization". In: arXiv preprint 883 arXiv:2007.06476 (2020). 884
- Nicolas Apfel and Xiaoran Liang. "Agglomerative Hierarchical Clustering for Se-|17|885 lecting Valid Instrumental Variables". In: arXiv preprint arXiv:2101.05774 (2021). 886
- Alessandra Marengoni et al. "Aging with multimorbidity: a systematic review of [18]887 the literature". In: Ageing research reviews 10.4 (2011), pp. 430–439. 888
- |19|Academy of medical sciences (Royaume uni). Multimorbidity: a priority for global 889 health research. Academy of medical sciences, 2018. 890
- Jane AH Masoli, Luke C Pilling, and Timothy M Frayling. "Genomics and multi-[20]891 morbidity". In: Age and Ageing 51.12 (2022), afac285. 892

⁸⁹³ [21] Verena Zuber et al. "Multi-response Mendelian randomization: Identification of
 ⁸⁹⁴ shared and distinct exposures for multimorbidity and multiple related disease out ⁸⁹⁵ comes". In: *The American Journal of Human Genetics* 110.7 (2023), pp. 1177–
 ⁸⁹⁶ 1199.

- ⁸⁹⁷ [22] Calypse B Agborsangaya et al. "Multimorbidity prevalence in the general popula-⁸⁹⁸ tion: the role of obesity in chronic disease clustering". In: *BMC Public Health* 13.1 ⁸⁹⁹ (2013), pp. 1–6.
- ⁹⁰⁰ [23] M Kivimaki et al. "Body-mass index and risk of obesity-related complex multimor⁹⁰¹ bidity: an observational multicohort study. Lancet Diabetes Endocrinol. 2022; 10:
 ⁹⁰² 253–63". In: Article PubMed PubMed Central (), p. 253.
- ⁹⁰³ [24] Susan Martin et al. "Disease consequences of higher adiposity uncoupled from its ad-⁹⁰⁴ verse metabolic effects using Mendelian randomisation". In: *Elife* 11 (2022), e72452.
- Andrew J Grant et al. "Noise-augmented directional clustering of genetic association data identifies distinct mechanisms underlying obesity". In: *PLoS Genetics* 18.1 (2022), e1009975.
- ⁹⁰⁸ [26] Luca Scrucca et al. "mclust 5: clustering, classification and density estimation using
 ⁹⁰⁹ Gaussian finite mixture models". In: *The R journal* 8.1 (2016), p. 289.
- ⁹¹⁰ [27] William G Cochran. "The comparison of percentages in matched samples". In:
 ⁹¹¹ Biometrika 37.3/4 (1950), pp. 256–266.
- ⁹¹² [28] Brendan Bulik-Sullivan et al. "An atlas of genetic correlations across human diseases and traits". In: *Nature genetics* 47.11 (2015), pp. 1236–1241.
- A. Belloni et al. "Sparse Models and Methods for Optimal Instruments With an Application to Eminent Domain". In: *Econometrica* 80.6 (2012), pp. 2369–2429.
 DOI: 10.3982/ecta9626.
- ⁹¹⁷ [30] Buhm Han and Eleazar Eskin. "Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies". In: *The American Journal of Human Genetics* 88.5 (2011), pp. 586–598.
- Jingshu Wang et al. "Causal inference for heritable phenotypic risk factors using heterogeneous genetic instruments". In: *PLoS genetics* 17.6 (2021), e1009575.
- [32] Kyoko Watanabe et al. "Functional mapping and annotation of genetic associations with FUMA". In: *Nature communications* 8.1 (2017), p. 1826.
- [33] D John Betteridge. "What is oxidative stress?" In: *Metabolism* 49.2 (2000), pp. 3–8.
- Prasenjit Manna and Sushil K Jain. "Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies". In: *Metabolic syndrome and related disorders* 13.10 (2015), pp. 423-444.
- [35] Heather K Vincent and Ann G Taylor. "Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans". In: *International journal of obesity* 30.3 (2006), pp. 400–418.
- ⁹³¹ [36] Taka-aki Matsuoka et al. "Glycation-dependent, reactive oxygen species-mediated
 ⁹³² suppression of the insulin gene promoter activity in HIT cells." In: *The Journal of*⁹³³ clinical investigation 99.1 (1997), pp. 144–150.

[37] Shigetada Furukawa et al. "Increased oxidative stress in obesity and its impact on metabolic syndrome". In: *The Journal of clinical investigation* 114.12 (2017), pp. 1752–1761.

- ⁹³⁷ [38] Panagiotis Lepetsos and Athanasios G Papavassiliou. "ROS/oxidative stress signaling in osteoarthritis". In: *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 1862.4 (2016), pp. 576–591.
- [39] Karol Tejchman, Katarzyna Kotfis, and Jerzy Sieńko. "Biomarkers and mechanisms of oxidative stress—last 20 Years of Research with an emphasis on kidney damage and renal transplantation". In: *International journal of molecular sciences* 22.15
 (2021), p. 8010.
- ⁹⁴⁴ [40] Zhe Lu et al. "Oxidative stress and psychiatric disorders: evidence from the bidi-⁹⁴⁵ rectional mendelian randomization study". In: *Antioxidants* 11.7 (2022), p. 1386.
- ⁹⁴⁶ [41] Pu Yifu. "Evidence for causal effects of polycystic ovary syndrome on oxidative
 ⁹⁴⁷ stress: a two-sample mendelian randomisation study". In: *BMC Medical Genomics*⁹⁴⁸ 16.1 (2023), p. 141.
- JD Crapo. "Oxidative stress as an initiator of cytokine release and cell damage".
 In: European Respiratory Journal 22.44 suppl (2003), 4s-6s.
- ⁹⁵¹ [43] K Ito et al. "Oxidative stress reduces histone deacetylase 2 activity and enhances
 ⁹⁵² IL-8 gene expression: role of tyrosine nitration". In: *Biochemical and biophysical*⁹⁵³ research communications 315.1 (2004), pp. 240–245.
- 954[44]Lars Wallentin et al. "Growth differentiation factor 15, a marker of oxidative stress955and inflammation, for risk assessment in patients with atrial fibrillation: insights956from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in957Atrial Fibrillation (ARISTOTLE) trial". In: Circulation 130.21 (2014), pp. 1847–9581858.
- ⁹⁵⁹ [45] Marie Verbanck et al. "Detection of widespread horizontal pleiotropy in causal
 ⁹⁶⁰ relationships inferred from Mendelian randomization between complex traits and
 ⁹⁶¹ diseases". In: *Nature genetics* 50.5 (2018), pp. 693–698.
- [46] Giovanni Davi et al. "Platelet activation in obese women: role of inflammation and oxidant stress". In: Jama 288.16 (2002), pp. 2008–2014.
- [47] Samina Salim. "Oxidative stress and psychological disorders". In: Current neuropharmacology 12.2 (2014), pp. 140–147.
- [48] Maureen Redza-Dutordoir and Diana A Averill-Bates. "Activation of apoptosis signalling pathways by reactive oxygen species". In: *Biochimica et Biophysica Acta* (BBA)-Molecular Cell Research 1863.12 (2016), pp. 2977–2992.
- ⁹⁶⁹ [49] James D Johnson and Dan S Luciani. "Mechanisms of pancreatic β -cell apoptosis ⁹⁷⁰ in diabetes and its therapies". In: *The Islets of Langerhans* (2010), pp. 447–462.
- ⁹⁷¹ [50] Marcello Del Carlo Jr and Richard F Loeser. "Cell death in osteoarthritis". In:
 ⁹⁷² Current rheumatology reports 10.1 (2008), pp. 37–42.
- ⁹⁷³ [51] Rodrigo Franco et al. "Oxidative stress, DNA methylation and carcinogenesis". In:
 ⁹⁷⁴ Cancer letters 266.1 (2008), pp. 6–11.
- ⁹⁷⁵ [52] Yingmei Niu et al. "Oxidative stress alters global histone modification and DNA methylation". In: *Free Radical Biology and Medicine* 82 (2015), pp. 22–28.

⁹⁷⁷ [53] Frances M Ashcroft. Ion channels and disease. Academic press, 1999.

- 978[54]Richard E Ostlund Jr et al. "The ratio of waist-to-hip circumference, plasma insulin979level, and glucose intolerance as independent predictors of the HDL2 cholesterol980level in older adults". In: New England Journal of Medicine 322.4 (1990), pp. 229–981234.
- [55] Rena R Wing et al. "Waist to hip ratio in middle-aged women. Associations with behavioral and psychosocial factors and with changes in cardiovascular risk factors." In: Arteriosclerosis and thrombosis: a journal of vascular biology 11.5 (1991), pp. 1250–1257.
- ⁹⁸⁶ [56] Gerd Schmitz and Margot Grandl. "The molecular mechanisms of HDL and asso⁹⁸⁷ ciated vesicular trafficking mechanisms to mediate cellular lipid homeostasis". In:
 ⁹⁸⁸ Arteriosclerosis, thrombosis, and vascular biology 29.11 (2009), pp. 1718–1722.
- ⁹⁸⁹ [57] Shao-Nian Yang and Per-Olof Berggren. "The role of voltage-gated calcium channels ⁹⁹⁰ in pancreatic β -cell physiology and pathophysiology". In: *Endocrine reviews* 27.6 ⁹⁹¹ (2006), pp. 621–676.
- ⁹⁹² [58] Eva Xepapadaki et al. "Impact of apolipoprotein A1-or lecithin: cholesterol acyltransferase⁹⁹³ deficiency on white adipose tissue metabolic activity and glucose homeostasis in
 ⁹⁹⁴ mice". In: *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 1865.6
 ⁹⁹⁵ (2019), pp. 1351–1360.
- ⁹⁹⁶ [59] Marie M Gleason, MS Medow, and Thomas N Tulenko. "Excess membrane choles⁹⁹⁷ terol alters calcium movements, cytosolic calcium levels, and membrane fluidity in
 ⁹⁹⁸ arterial smooth muscle cells." In: *Circulation Research* 69.1 (1991), pp. 216–227.
- ⁹⁹⁹ [60] Eva Xepapadaki et al. "HDL and type 2 diabetes: the chicken or the egg?" In: ¹⁰⁰⁰ Diabetologia 64 (2021), pp. 1917–1926.
- [61] Miriam S Udler et al. "Type 2 diabetes genetic loci informed by multi-trait asso ciations point to disease mechanisms and subtypes: a soft clustering analysis". In:
 PLoS medicine 15.9 (2018), e1002654.
- [62] Donald W. K. Andrews. "Consistent Moment Selection Procedures for Generalized Method of Moments Estimation". In: *Econometrica* 67.3 (1999), pp. 543–563. DOI: 10.1111/1468-0262.00036.
- [63] Andrew Khor et al. "Diabetes mellitus is not a risk factor for osteoarthritis". In: $RMD \ open \ 6.1 \ (2020), \ e001030.$
- [64] Ana Luiza Arruda et al. "Genetic underpinning of the comorbidity between type 2 diabetes and osteoarthritis". In: *The American Journal of Human Genetics* 110.8 (2023), pp. 1304–1318.
- ¹⁰¹² [65] Joe H Ward Jr. "Hierarchical grouping to optimize an objective function". In: *Jour-*¹⁰¹³ *nal of the American statistical association* 58.301 (1963), pp. 236–244.
- [66] William M Rand. "Objective criteria for the evaluation of clustering methods". In:
 Journal of the American Statistical association 66.336 (1971), pp. 846–850.
- [67] Anubha Mahajan et al. "Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps". In: *Nature genetics* 50.11 (2018), pp. 1505–1513.
- [68] FinnGen. FinnGen Documentation of R8 release. 2022. URL: https://finngen.
 gitbook.io/documentation/.

- ¹⁰²¹ [69] Martin Kircher et al. "A general framework for estimating the relative pathogenicity ¹⁰²² of human genetic variants". In: *Nature genetics* 46.3 (2014), pp. 310–315.
- ¹⁰²³ [70] Daifeng Wang et al. "Comprehensive functional genomic resource and integrative ¹⁰²⁴ model for the human brain". In: *Science* 362.6420 (2018), eaat8464.
- 1025[71]Monique GP Van Der Wijst et al. "Single-cell RNA sequencing identifies celltype-1026specific cis-eQTLs and co-expression QTLs". In: Nature genetics 50.4 (2018), pp. 493-1027497.
- ¹⁰²⁸ [72] Benjamin J Schmiedel et al. "Impact of genetic polymorphisms on human immune ¹⁰²⁹ cell gene expression". In: *Cell* 175.6 (2018), pp. 1701–1715.
- [73] Urmo Võsa et al. "Unraveling the polygenic architecture of complex traits using
 blood eQTL metaanalysis". In: *BioRxiv* (2018), p. 447367.
- ¹⁰³² [74] Elin Grundberg et al. "Mapping cis-and trans-regulatory effects across multiple ¹⁰³³ tissues in twins". In: *Nature genetics* 44.10 (2012), pp. 1084–1089.
- [75] Bernard Ng et al. "An xQTL map integrates the genetic architecture of the human brain's transcriptome and epigenome". In: *Nature neuroscience* 20.10 (2017), pp. 1418–1426.
- ¹⁰³⁷ [76] Menachem Fromer et al. "Gene expression elucidates functional impact of polygenic
 ¹⁰³⁸ risk for schizophrenia". In: *Nature neuroscience* 19.11 (2016), pp. 1442–1453.
- 1039[77]Adaikalavan Ramasamy et al. "Genetic variability in the regulation of gene expression in ten regions of the human brain". In: Nature neuroscience 17.10 (2014),1040pp. 1418–1428.
- ¹⁰⁴² [78] GTEx Consortium et al. "The Genotype-Tissue Expression (GTEx) pilot analysis: ¹⁰⁴³ multitissue gene regulation in humans". In: *Science* 348.6235 (2015), pp. 648–660.
- [79] GTEx Consortium Lead analysts: Aguet François 1 Brown Andrew A. 2 3 4 Castel
 Stephane E. 5 6 Davis Joe R. 7 8 He Yuan 9 Jo Brian 10 Mohammadi Pejman 5 6
 Park YoSon 11 Parsana Princy 12 Segrè Ayellet V. 1 Strober Benjamin J. 9 Zappala
 Zachary 7 8 et al. "Genetic effects on gene expression across human tissues". In:
 Nature 550.7675 (2017), pp. 204–213.
- [80] Arthur Liberzon et al. "Molecular signatures database (MSigDB) 3.0". In: *Bioinformatics* 27.12 (2011), pp. 1739–1740.
- [81] Martina Kutmon et al. "WikiPathways: capturing the full diversity of pathway
 knowledge". In: Nucleic acids research 44.D1 (2016), pp. D488–D494.
- [82] Jacqueline MacArthur et al. "The new NHGRI-EBI Catalog of published genomewide association studies (GWAS Catalog)". In: *Nucleic acids research* 45.D1 (2017),
 pp. D896–D901.
- [83] Benjamin B Sun et al. "Genomic atlas of the human plasma proteome". In: Nature 558.7708 (2018), pp. 73–79.
- 1058[84]Alexander Gudjonsson et al. "A genome-wide association study of serum proteins1059reveals shared loci with common diseases". In: Nature communications 13.1 (2022),1060p. 480.
- [85] Ari V Ahola-Olli et al. "Genome-wide association study identifies 27 loci influencing concentrations of circulating cytokines and growth factors". In: *The American Journal of Human Genetics* 100.1 (2017), pp. 40–50.

1064 1065	[86]	Marita Kalaoja et al. "The role of inflammatory cytokines as intermediates in the pathway from increased adiposity to disease". In: <i>Obesity</i> 29.2 (2021), pp. 428–437.
1066 1067 1068	[87]	Niamh Mullins et al. "Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology". In: <i>Nature genetics</i> 53.6 (2021), pp. 817–829.
1069 1070 1071	[88]	Naomi R Wray, Patrick F Sullivan, et al. "Genome-wide association analyses iden- tify 44 risk variants and refine the genetic architecture of major depression. bioRxiv". In: URL https://www. biorxiv. org/content/early/2017/07/24/167577 (2017).
1072 1073	[89]	Dmitry Shungin et al. "New genetic loci link adipose and insulin biology to body fat distribution". In: <i>Nature</i> 518.7538 (2015), pp. 187–196.
1074 1075	[90]	"Discovery and refinement of loci associated with lipid levels". In: <i>Nature genetics</i> 45.11 (2013), pp. 1274–1283.
1076 1077	[91]	"A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease". In: <i>Nature genetics</i> 47.10 (2015), pp. 1121–1130.
1078 1079 1080	[92]	Frank Windmeijer et al. "The confidence interval method for selecting valid instru- mental variables". In: Journal of the Royal Statistical Society: Series B (Statistical Methodology) 83.4 (2021), pp. 752–776.

1081 Funding

This work was supported by the Strategic Priority Fund "Tackling multimorbidity at scale" programme (grant number MC/MR/WO14548/1) delivered by the Medical Research Council and the National Institute for Health and Care Research in partnership with the Economic and Social Research Council and in collaboration with the Engineering and Physical Sciences Research Council. Nicolas Apfel is supported by the ESRC grant EST013567/1.



1087